Extended Data Fig. 2: Dynamic characterization of TCR landscape.
From: Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results
a, TCR sequencing of tumor (pre-treatment), pre- (P0) and post-treatment (P1) blood T cells (patients SH1-SH7, top-bottom). Top 10 differential blood clonotypes shown in serial blood (left) and tumor (right). b, Longitudinal changes in dominant tumor/blood clonotypes (circle size = clonal frequency; bright = persistent clones). MPR patients maintained pretreatment-dominant clones post-treatment. c, Grantham distance-based similarity of top 50 intratumoral TCR CDR3b clones. Red highlights maximally expanded clones. d, Bar plot of TCR and BCR clonotypes across all T cells and B cells in MPR or noMPR groups from P0, P1 and tumors. One clonotype consists strictly of one paired α-/β-chain V(D)J TCR. e, Pie chart of the antigen specificity of detected TCRs when considering α-, β-, and paired strands. CMV, cytomegalovirus; EBV, Epstein-Barr virus; InfluenzaA, influenza A virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; HS, Homo sapiens antigen; HIV-1, human immunodeficiency virus 1; HCV, hepatitis C virus; YFV, yellow fever virus; DEV, dengue virus. f, Representative immunofluorescence images of senescent markers P16 and P21 on paraffin sections from MPR and noMPR patients in two patient cohorts (Cohort1 n = 50, Cohort2 n = 61).
